title: Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma.
authors.forename: Saranya
authors.initials: S
authors.lastname: Chumsri
authors.forename: Merry
authors.initials: M
authors.lastname: Zhao
authors.forename: Michael
authors.initials: M
authors.lastname: Garofalo
authors.forename: Angelika
authors.initials: A
authors.lastname: Burger
authors.forename: Anne
authors.initials: A
authors.lastname: Hamburger
authors.forename: Frank
authors.initials: F
authors.lastname: Zhao
authors.forename: Aaron
authors.initials: A
authors.lastname: Rapoport
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011494:Protein Kinases / Q000187:drug effects*; D016879:Salvage Therapy; D020123:Sirolimus / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy*; D058570:TOR Serine-Threonine Kinases; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus